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Background — It is now generally accepted that calci c aortic 
valve disease is an atherosclerotic-like process. Recent studies 
in an experimental model of aortic valve sclerosis demonstrated 
the presence of tissue factor (TF), the main contributor to 
atherosclerotic plaque thrombogenicity, in diseased valve 
lea ets. We assessed the hypothesis that human aortic valve 
disease is an atherosclerotic-like process in which TF plays 
an important role and evaluated the valvular expression and 
localization of TF and other components of atherosclerosis.
Methods — Calci ed aortic valves (n=52) were obtained from patients 
undergoing aortic valve replacement. Lea et structure, cellular 
and lipid in ltration and expression of TF, its inhibitors, VEGF and 
other components of atherosclerosis were evaluated by histological 
and immunohistochemical staining. TF, TFPI, osteopontin, MMP-
9, TIMP-1 and VEGF antigen were measured by ELISA and TF and 
alkaline phosphatase activity were determined using chromogenic 
assays. Finally, we performed semi-quanti cation of TF transcripts 
by RT- PCR and further analyzed protein expression by Western 
blot.
Results — Histological and immunohistochemical staining of the 
valve lea ets revealed neovascularisation at the centre of the 
lesions, overall macrophage and myo broblast in ltration and 
the abundant presence of MMP-9. On the other hand, TF and TFPI 
were associated with calci cation and extracellular lipid deposits 
in the  brosa and the subendothelial layer of the aortic side of the 
lea ets. Correspondingly, TF antigen and activity were found to be 
higher in calci ed regions of the valve lea ets (733.29 ± 70.49 pg/
mg vs 429.40 ± 73.17 pg/mg and 144.75 ± 14.65 pg/mg vs 40.15 ± 
6.19 pg/mg respectively (p<0.0001)). Similar results were found 
for osteopontin, MMP-9, TIMP-1 and VEGF. In contrast, TFPI antigen 
was found to be much lower in these calci ed regions (722.54 ± 
153.92 pg/mg vs 2459.28 ± 285.36 pg/mg (p<0.0001)).
Conclusion — These results demonstrate that aortic valve lesions 
display several characteristics of atherosclerosis, including TF 
expression. In addition, we showed that TF is colocalized with 
calci cation and lipid deposition. Further studies are now set up to 
evaluate the role of TF in aortic valve disease and its association 
with other components of the atherosclerotic process.
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Introduction — CD163 is a macrophage receptor of haptoglogin/
haemoglobin complexes responsible for clearance of hemogloin. 
It has been recently suggested to be a potential scavenger 
receptor for TWEAK (Tumor necrosis factor-like weak inducer of 
apoptosis). TWEAK levels were reported to be decreased in carotid 
atherosclerosis. Our hypothesis is that decreased circulating 
TWEAK could be paralleled by an increased presence of CD163-
expressing macrophage in atherosclerotic plaques. Since peripheral 
artery disease (PAD) is an important manifestation of systemic 
atherosclerosis, we have assessed the levels of circulating TWEAK-
CD163 in PAD.
Methods and Results — Patients with PAD (n=184) had lower TWEAK 
(169.2±8.3 vs 211.9±15.4 pg/mL ; p<0.05) and higher sCD163 
(408.1±14.5 vs 317.4±8.4 ng/mL ; p<0.05) plasma concentration 
than age-matched controls (n=330). After strati cation according 
to the severity of disease, we observed that TWEAK/sCD163 ratio 
was signi cantly decreased in those patients with higher degree 
of disease (0.39±0.06 vs 0.66±0.08, p<0.05) relative to the other 
groups. Analysis of conditioned medium obtained from cultured 
human atherosclerotic femoral plaque samples (n=38) and healthy 
aortas (n=14) revealed that higher amount of sCD163 was released 
by the atherosclerotic tissue, whereas TWEAK presented the 
opposite trend.
Conclusions — Our results suggest that CD163/TWEAK plasma 
ratio could be a potential biomarker of clinical peripheral artery 
disease. We can hypothesized that decreased levels of circulating 
TWEAK observed in atherosclerosis may be the result of a trapping 
by plaque macrophages through their CD163.
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Purpose — Adenosine, acting through four types of receptors 
(A1, A2a, A2b, A3), is anti-in ammatory and cardioprotective. 
Since Toll-Like Receptor 4 (TLR4), a receptor involved in 
innate immunity, has recently been shown to mediate adverse 
left ventricular remodeling after myocardial infarction (MI), 
we sought to determine whether adenosine acts on the TLR4 
pathway.
Methods — Primary human macrophages obtained after in 
vitro differentiation of blood monocytes isolated from healthy 
volunteers and patients with acute MI were treated with 
adenosine (10 m), adenosine analogs, and/or lipopolysaccharide 
(LPS, 100 ng/mL). Transgenic mice bearing a cardiac-speci c and 
externally-regulatable overexpression of A1 or A2a receptors 
were used to determine the receptor involved. Flow cytometry, 
immunoblotting, quantitative PCR and ELISA were used to 
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measure expression levels of TLR4, Tumor Necrosis Factor-α 
(TNF-α), TNF receptor-associated factor -6 (TRAF-6), and 
β-arrestins.
Results — Consistently with others, we observed that the TLR4 
pathway is activated following MI. In LPS-treated macrophages, 
adenosine decreased cell surface expression of TLR4, resulting in 
a decrease of TNF-α production. This anti-in ammatory effect 
was also observed when macrophages were challenged with 
endogenous TLR4 ligands such as hyaluronic acid or heparan 
sulfate. Inhibition of TNF-α production by adenosine was stronger 
in macrophages isolated from MI patients compared with healthy 
volunteers. The effect was replicated by agonists of A2a receptors 
and blocked by antagonists of A2a receptors. Over-expression of 
the A1 and A2a receptors in mice both resulted in a decrease of 
TLR4 and TRAF-6 expression in the heart. Co-immunoprecipitation 
studies indicated that adenosine enhances the binding of 
β-arrestins to TRAF-6, thus interrupting TLR4 signaling.
Conclusion — Adenosine down-regulates in ammation through 
interference with the TLR4 pathway. This mechanism involves 
enhanced binding of β-arrestins to TRAF-6 in the presence of 
adenosine. This result may have important implications as it 
explains some anti-in ammatory and cardioprotective properties 
of adenosine.
A011
MATRIX METALLOPROTEINASE-12 GENE 
REGULATION BY PPAR ALPHA AGONIST IN HUMAN 
MONOCYTE-DERIVED MACROPHAGES
I. JGUIRIM-SOUISSI 1,2, L. BILLIET 2, C. CUAZ-PEROLIN 2, 
M.-N. SLIMANE 1, M. ROUIS 2
1 Research laboratory on atherosclerotic biological and genetic 
factors, Faculty of Medicine., Monastir, Tunisia
2 UMR 7079 Physiologie et Physiopathologie, Université Pierre et 
Marie Curie-Paris 6, CNRS, Paris cedex 5, France
MMP-12, a macrophage-speci c matrix metalloproteinase with large 
substrate speci city, has been reported to be highly expressed in 
mice, rabbits and human atherosclerotic lesions. Increased MMP-
12 from in ammatory macrophages is associated with several 
degenerative diseases such as atherosclerosis. Our results showed 
that IL-1b, a proin ammatory cytokine found in atherosclerotic 
plaques, increased both mRNA and protein levels of MMP-12 in 
human monocyte-derived macrophages (HMDM). Since peroxisome 
proliferator-activated receptors (PPAR) such as PPARa and PPARg 
are expressed in macrophages and because PPARs activation exert 
an anti-in ammatory effect on vascular cells ; we have investigated 
the effect of PPARa and g isoforms on MMP-12 regulation in HMDM. 
Our results showed that MMP-12 expression (mRNA and protein) was 
down regulated in IL-1b-treated macrophages only in the presence 
of a speci c PPARa agonist GW647 in a dose-dependent manner. In 
contrast, this inhibitory effect was abolished in IL-1b-stimulated 
peritoneal macrophages isolated from PPARa-/- mice and treated 
with the GW647 PPARa agonist. Moreover, reporter gene transfection 
experiments using different MMP-12 promoter constructs showed 
a reduction of the promoter activities by ~50 % in IL-1b-stimulated 
PPARa pretreated cells. However, MMP-12 promoter analysis did not 
reveal the presence of a PPRE response element. The IL-1b effect 
is known to be mediated through the AP-1 binding site. Mutation of 
the AP-1 site, which is located at -81 in the MMP-12 promoter region 
relative to the transcription start site, followed by transfection 
analysis and gel shift experiments revealed that the inhibitory effect 
was the consequence of the protein-protein interaction between GW 
647-activated PPARa and c-Fos or c-Jun transcription factors, leading 
to inhibition of their binding to the AP-1 motif. These studies suggest 
that PPARa agonists may be used as a therapeutically, not only for 
lipid disorders, but also to prevent in ammation and atheromatous 
plaque rupture, where their ability to inhibit MMP-12 expression in 
HMDM may be bene cial.
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Le raccourcissement des télomères est un déterminant majeur du 
vieillissement cellulaire. Des études in vitro montrent qu’un stress 
oxydant accru serait responsable d’une attrition plus marquée des 
télomères. Par ailleurs, des études cliniques portant sur l’association 
athérothrombose — longueur des télomères ont montré que les sujets 
athéromateux avaient des télomères leucocytaires plus courts. Le but 
de cette étude est d’étudier la dynamique des télomères sur des tissus 
atteints ou non par l’athérosclérose. Différents paramètres artériels 
(PAS et PAD) et métaboliques (diabète, dyslipidémie, BMI, tabagisme) 
ont été évalués au sein de 28 hommes et de 9 femmes (âge moyen : 
70 ± 7,8 ans) présentant différentes pathologies cardiovasculaires. La 
longueur moyenne des télomères a été mesurée par Southernblotting 
sur des tissus artériels atteints de l’athérome, des tissus artériels non 
athérogènes, du tissus graisseux et du sang. Les tissus athérogènes de 
l’arbre aortique constitué par la valve aortique, l’aorte ascendante, 
l’aorte abdominale, l’artère iliaque et l’artère fémorale, présentent 
des télomères plus courts que ceux retrouvés dans les vaisseaux non 
athérogènes (artère mammaire et veine saphène). En présence de 
facteurs de risque cardiovasculaire (HTA, diabète type 2, tabagisme), 
seuls les tissus athérogènes présentent des TRF plus courts, les TRF 
des tissus non athérogènes étant essentiellement in uencés par 
l’âge. Notre étude montre aussi qu’il existe, uniquement dans l’arbre 
aortique, une relation inverse entre la pression pulsée, indice de 
rigidité aortique, et la longueur des télomères. Les différences de TRF 
observées entre tissus sains et tissus athéromateux pourraient suggérer 
l’existence d’une régulation locale de la taille des télomères pouvant 
être due à la présence du processus in ammatoire caractéristique de 
l’athérosclérose, et d’un stress oxydant accru, ces deux processus 
étant fréquemment rencontrés chez les patients présentant des 
facteurs de risque cardiovasculaires tels que l’HTA, le diabète, et une 
augmentation de la rigidité artérielle.
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